Objectives-To establish the eVect of the atypical neuroleptic clozapine on chorea, voluntary motor performance, and functional disability in patients with Huntington's disease. Methods-Thirty three patients with Huntington's disease participated in a double blind randomised trial. A maximum of 150 mg/day clozapine or placebo equivalent was given for a period of 31 days. Assessments were performed in the week before and at the last day of the trial. Chorea was scored using the abnormal involuntary movement scale (AIMS), the chorea score of the unified Huntington's disease rating scale (UHDRS), and judgement of video recordings. Voluntary motor performance was assessed using the UHDRS motor scale. Patients and their partners completed a questionnaire regarding functional disability. Twelve patients already used other neuroleptic medication, which was kept unchanged during the trial period. Results of neuroleptic naive and neuroleptic treated patients were analysed separately. Results-Clozapine tended to reduce chorea in neuroleptic naive patients only (AIMS); improvement seemed more pronounced in patients receiving higher doses of clozapine. Other measures of chorea (UHDRS chorea score, video ratings) showed no improvement. Clozapine had no beneficial eVect on chorea in patients already receiving neuroleptic medication. Voluntary motor performance did not improve with clozapine. Neuroleptic naive patients reported aggravation of functional disability, possibly reflecting the frequent occurrence of side eVects. Adverse reactions forced trial termination in six patients and dose reduction in another eight, and consisted mainly of drowsiness, fatigue, anticholinergic symptoms, and walking diYculties. Conclusions-Clozapine has little beneficial eVect in patients with Huntington's disease, although individual patients may tolerate doses high enough to reduce chorea. Because adverse reactions are often encountered, clozapine should be used with restraint in this patient group.
Treatment of patients with Huntington's disease is aimed at reducing behavioural, psychiatric, and motor symptoms. Neuroleptic drugs are most commonly used for the treatment of chorea, but results have been rather disappointing. Although most classic neuroleptic drugs reduce chorea, [1] [2] [3] these drugs fail to improve functional capacity 1 4 or even aggravate disability. 5 The inability of classic neuroleptic drugs to improve functional capacity, despite ameliorating chorea, is conceivably due to suppression of voluntary motor activity. 2 6 7 Furthermore, tardive dyskinesia has occasionally been reported in patients with Huntington's disease treated with classic neuroleptic drugs. 6 8 The atypical neuroleptic clozapine, which in psychiatry is used for schizophrenic patients not responsive to classic neuroleptic drugs, 9 has an extremely low incidence of extrapyramidal side eVects 10 and might thus be favourable in the treatment of chorea. Indeed, two previous reports seemed promising, but results were inconclusive because of small patient numbers or lack of placebo control. 11 12 Other investigators failed to find a pronounced eVect of clozapine on chorea in Huntington's disease. 13 14 Therefore, we conducted a double blind placebo controlled trial in 33 patients with Huntington's disease, in which we analysed the eVects of clozapine on chorea, voluntary motor performance, and functional disability.
Patients and methods

PATIENTS AND TRIAL DESIGN
Thirty three patients from our outpatient department with clinically and genetically established Huntington's disease and typical choreatic movements participated in the trial. Informed consent was obtained from all patients. Twelve patients (three men; mean age 54.7 (range 42-73) years; mean duration of disease 11.7 (range 4.8-25.8) years) were on neuroleptic medication, which remained unchanged during the trial. Neuroleptic drugs used were pimozide (five patients), tiapride (three), sulpiride (two), zuclopentixol (two), haloperidol (one), pipamperon (one), and perphenazine (one). The remaining 21 patients (12 men; mean age 44.8 (range 26-61) years; mean disease duration 8.1 (range 2.7-24.0) years) were neuroleptic-naive. Demented or psychotic patients, as well as patients with a history of clozapine use, were excluded from the trial.
Clozapine or placebo was randomly assigned to the patients by the hospital pharmacist, who was not involved in the assessment of the patients. Both the patient and the clinician remained blind to the treatment until all patients had completed the trial. Treatment covered a period of 31 days. Clozapine or placebo equivalent was started at 25 mg/day and increased every other day, following a generally accepted schedule leading to satisfactory benefit/risk ratios and compliance in schizophrenic patients. 10 18 Dosage was increased until a predefined maximum 150 mg/day was reached or side eVects prevented further increase. This maximum dose was chosen because (1) Bonuccelli et al 12 noted pronounced reduction of chorea by clozapine at 150 mg/day, and (2) higher doses were expected to produce more adverse reactions. 10 18 19 Treatment was divided in four daily doses, with the larger dose given at the end of day to minimise the risk of daytime somnolence.
ASSESSMENT OF TREATMENT EFFECTS
Assessments were performed four days before and on the last day of the trial period, for every patient at the same time of day. Chorea was clinically rated by one of us (RACR) with the abnormal involuntary movement scale (maximum score: 36) 15 as well as the UHDRS chorea score (maximum score: 28). 16 Furthermore, video recordings were made under standard conditions from all patients while sitting as relaxed as possible in a chair for one minute. For every patient, the two recordings, before and at the end of the trial, were randomly mixed by a technician and blindly judged by two of us (JPPV and RACR). Consensus was reached for global diVerences in severity of chorea between the two video fragments. After breaking the treatment code, these global judgements were translated in terms of improvement, worsening, or no change in chorea with therapy compared with baseline.
To study the eVects of clozapine on voluntary motor performance, the following items of the UHDRS motor assessment 16 were used: dysarthria, tongue protrusion, finger tapping, rapid alternating movements, Luria's fist-edgepalm test, rigidity, bradykinesia, gait, tandem walking, and postural stability (retropulsion). The sum score of this assessment was used for analyses (maximum score 40).
Under supervision of one of us (JPPV) patients completed a questionnaire which consisted of 21 items regarding daily activities. The questionnaire was a modification of a list validated by Brown et al 17 to rate functional disability in patients with Parkinson's disease. On a five point scale, patients indicated whether they could perform the activity without diYculty (0 points), with some diYculty, with great diYculty, only with help, or not at all (4 points; maximum total score 84). If possible, partners were asked to complete the questionnaire regarding the patient's performance as well. At the end of the trial, patients and partners completed the same questionnaire to judge performance during the last week of the trial. Furthermore, patients were asked whether in general they had felt better, worse, or unchanged during the last week of the trial compared with before the trial.
ADVERSE REACTIONS
The occurrence of side eVects was closely monitored by an investigator not involved in the clinical assessments of the patients but nevertheless blind to the treatment (SS). Patients could approach the investigator by telephone in case of possible side eVects and all patients were contacted at day 10 of the trial. Guided by the occurrence and severity of possible side eVects, the individual optimum daily dose of clozapine or placebo equivalent was determined. If appreciable side eVects occurred, doses were either reduced and kept at a lower level or increased more slowly. In all patients, the daily dose was kept constant during the last 21 days of the trial. Blood samples were monitored weekly for changes in liver enzymes and white blood cell count by SS, who decided on trial suspension whenever predefined out of range values were noted. To guarantee blind assessment of outcome measures, blood laboratory values and the occurrence of side eVects remained unknown to the other investigators. At the end of the trial, patients were specifically asked for the occurrence of all known side eVects of clozapine. 10 18 19 STATISTICAL ANALYSES Results were analysed for neuroleptic naive and neuroleptic treated patients separately to reduce any confounding influence of concomitant neuroleptic medication. Patients in whom severe adverse reactions had forced breaking of the treatment code were excluded from further analyses. Student's t tests were used to show pretrial differences between the clozapine and placebo groups in any of the variables. Treatment eVects were evaluated by calculating the diVerences between scores before and at the end of the trial. These diVerences were compared between placebo and clozapine using analysis of covariance (ANCOVA), taking baseline scores into account to minimise the eVect of pretrial between group disparities. Because multiple variables were tested, P values < 0.01 were regarded as indicative of significant diVerences.
Results
BASELINE COMPARISON
In seven patients, trial suspension was necessary. These patients did not diVer significantly from those who completed the trial in any of the variables studied (Student's t test), and were excluded from further analyses. From the 26 patients who completed the trial, eight used neuroleptic medication whereas the remaining 18 were neuroleptic naive. Results of neuroleptic naive and neuroleptic treated patients were analysed separately. To show any pretrial diVerences between the clozapine and placebo groups, baseline values of the test variables were compared by Student's t tests. In neuroleptic free patients the clozapine group tended to have more chorea than the placebo group (P = 0.04), whereas in neuroleptic treated patients the placebo group scored significantly worse on functional disability (P< 0.01). No pretreatment diVerences were found in any of the other test variables (table 1) .
TREATMENT EFFECTS IN NEUROLEPTIC NAIVE AND NEUROLEPTIC TREATED PATIENTS
Because pretreatment diVerences would frustrate an unequivocal interpretation of treatment eVects, ANCOVA was used to investigate the eVects of clozapine and placebo, taking pretreatment values into account as covariate.
For neuroleptic naive patients, chorea tended to be reduced by clozapine (AIMS and UHDRS chorea score; table 2). Video recordings were judged as uninfluenced by medication in 57% of patients treated with clozapine, compared with 46% of placebo treated patients. Reduction of chorea was found in 43% with clozapine and 46% with placebo (table 3) . No diVerences in voluntary motor performance were found between clozapine and placebo treated patients (table 2). Self evaluated disability was aggravated by clozapine compared with placebo, although this was not confirmed by ratings made by partners (table 2) . When patients were asked how they in general judged the last trial week, 29% of the neuroleptic naive patients had felt worse with clozapine, compared with 9% of the placebo group (table 3) .
In neuroleptic treated patients, clozapine had no significant influence on any of the test variables compared with placebo (ANCOVA, table 2). Results of global video judgements and patient's opinion of the last trial week are diYcult to interpret because of the few patients in this group (table 3) .
Side eVects had prevented increase of clozapine dose to the predefined maximum of 150 mg/day in most of the patients, which might have tapered the eVect on chorea. We found more pronounced reduction of chorea in three patients receiving 150 mg/day of clozapine. However, establishing a formal dose-eVect relation was not the primary aim of our study, and patient numbers were too small to consider this issue statistically.
ADVERSE REACTIONS
When asked for the occurrence of adverse eVects, all patients treated with clozapine claimed to have experienced some side eVects (table 4). Reduction of clozapine dose was necessary in eight patients; individual optimum doses tolerated were 50 mg/day (three patients), 75 mg/day (one), 100 mg/day (three), and 125 mg/day (one). Another six patients were unable to complete the trial because of side eVects (table 4). Side eVects most often reported were drowsiness (14 patients), dizziness (six), walking diYculties (six), fatigue (four), and hypersalivation (four). In seven patients, clozapine induced increase in liver enzymes was seen, forcing dose reduction in one patient and trial suspension in two. Laboratory values returned to normal within four weeks after clozapine withdrawal. One patient experienced a generalised epileptic seizure while receiving clozapine at 150 mg/day. Extensive history analysis showed no other cause for this epileptic seizure. After clozapine was withdrawn, no further seizures were experienced. In the placebo group, one patient could not complete the trial due to intercurrent illness.
Discussion
The results of this placebo controlled double blind randomised trial indicate that clozapine †Reason for dose reduction (number of patients): drowsiness (three); confusion (one); urinary incontinence (one); walking diYculties (one); dizziness (one); increased liver enzymes (one). ‡Reason for trial suspension (number of patients): urinary incontinence (one); walking/speaking diYculties (one); orthostatic hypotension/syncope (one); increased liver enzymes (two); epileptic seizure (one).
is of little use in the treatment of chorea in patients with Huntington's disease. Although clozapine tended to reduce chorea rated with the AIMS and the UHDRS chorea scale in neuroleptic free patients, especially in patients receiving higher doses of clozapine, the frequent occurrence of side eVects prevented dose increase to the predefined maximum of 150 mg/day in most of the patients. Judgement of video recordings and assessment of voluntary motor performance showed no diVerences between clozapine and placebo. Moreover, patients reported more severe functional disability while receiving clozapine. Clozapine did not influence any of the variables in patients already receiving other neuroleptic medication.
Our findings corroborate the small eVect of clozapine on chorea in patients with Huntington's disease noted by others. 13 14 Caine et al 11 studied the eVect of clozapine on various dyskinaesiae in a placebo controlled crossover trial, in which three patients with Huntington's disease participated. In their study, chorea was reduced in two patients at doses of 200 mg/day and 500 mg/day respectively, whereas the third patient with Huntington's disease failed to complete the trial due to confusion, slurred speech, and severe orthostatic hypotension.
11
This is in keeping with our results showing considerable reduction of chorea in three patients who tolerated the predefined maximum dose of 150 mg/day in the face of noticeable adverse reactions in other patients. The results of our study largely contradict the findings of Bonuccelli et al, 12 who noted a striking reduction of chorea (without significant side eVects) at clozapine doses as low as 50 mg/day in an open label trial conducted on five patients with Huntington's disease. Possibly, their dose schedule (25 mg/day in week 1, 50 mg/day in week 2, and 150 mg/day in week 3) might be favourable with regard to side eVects, although some of our patients did not even tolerate 50 mg/day at day 10. Nevertheless, the discrepancy between the findings of Bonuccelli et al 12 and the results of the present study underscores the need for placebo control in the evaluation of possible therapeutic agents.
The limited eVect of clozapine on chorea might be explained by its relatively low D2 dopaminergic antagonistic properties. D2 receptor containing striatal projection neurons towards the external pallidal segment are involved in an indirect cortical-basal ganglialcortical feedback loop which is normally active in the suppression of involuntary motor activity. [20] [21] [22] [23] Preferential loss of these neurons is thought to be the pathophysiological basis of chorea in patients with Huntington's disease. [24] [25] [26] Nigrostriatal dopaminergic input yet further inhibits activity of this striatal cell population, 20 22 which is probably why D2 antagonising agents ameliorate chorea. 7 Both in vitro and in vivo studies have shown the low aYnity of clozapine for D2 receptors compared with classic neuroleptic compounds, [27] [28] [29] conceivably limiting its antichoreic potencies in Huntington's disease. The intrinsic anticholinergic properties of clozapine might even counteract a reduction of chorea in patients with Huntington's disease, 30 possibly by blockade of acetylcholine mediated stimulation of striatal projection neurons towards the external pallidal segment. 20 22 D2 receptor occupancy rises when higher doses of clozapine are administered, 27 which might explain our finding that reduction of chorea seemed more pronounced in patients receiving higher doses. This is also in keeping with the reduction of chorea in two patients with Huntington's disease treated with high doses of clozapine noted by Caine et al 11 , as well as with the dose-eVect relation reported by Bonuccelli et al. 12 The frequent occurrence of side eVects can explain why more patients felt worse with clozapine than with placebo, as well as why self evaluated disability tended to worsen. Our findings corroborate earlier reports regarding side eVects in patients with Huntington's disease treated with clozapine. Caine et al noted significant adverse reactions in all their patients, compromising the patients' functioning and "ability to perform routine self care tasks". 11 Pronounced sedation of most patients with Huntington's disease was described by Colosimo et al, even at clozapine doses as low as 25 mg/day.
14 In this respect, the absence of any significant side eVect as reported by Bonuccelli et al 12 seems unusual. Patients with organic brain disease seem to be more prone to adverse reactions of clozapine, 18 so special care should be taken in this patient group.
In conclusion, there seems to be little place for clozapine in the treatment of chorea in patients with Huntington's disease. Clozapine only tended to reduce chorea in patients not using other neuroleptic medication, whereas functional disability seemed worsened. The frequent occurrence of, in some cases severe, adverse reactions probably underlies the second finding. Some individual patients tolerated clozapine at doses high enough to reduce chorea. Future studies might consider early identification of these responders and the value of alternative dose schedules. Based on the data available at present, clozapine should be used with reserve in patients with Huntington's disease.
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